|
Jul 26, 2006
|
Affymax Appoints Jeffrey H. Knapp as Chief Commercialization Officer
|
7.2 KB |
|
| |
PALO ALTO, Calif., July 26, 2006 - Affymax, Inc., a clinical-stage pharmaceutical company, today announced the appointment of Jeffrey H. Knapp as chief commercialization officer. Mr. Knapp, who has nearly 20 years of experience in the pharmaceutical and biotech industries, joins Affymax as a member of the senior management team. "Jeff...
|
|
Jun 27, 2006
|
Affymax And Takeda Announce Comprehensive Global Agreement For Development And Commercialization Of Hematide™ For Anemia
|
12.7 KB |
|
| |
Palo Alto , CA and Osaka, Japan
June 27, 2006
Affymax, Inc. (Affymax) and Takeda Pharmaceutical Company Limited (Takeda) today announced that the companies have entered...
|
|
Jun 1, 2006
|
Affymax Appoints Kay Slocum As Senior Vice President Of Human Resources
|
9.9 KB |
|
| |
Palo Alto , CA
June 1, 2006
Affymax, Inc., a clinical-stage pharmaceutical company, today announced the appointment of Kay Slocum as senior vice president of human resour...
|
|
May 18, 2006
|
Affymax Appoints John P. Walker To Board Of Directors
|
10.0 KB |
|
| |
Palo Alto , CA
May 18, 2006
Affymax, Inc., a clinical-stage pharmaceutical company, today announced the appointment of John P. Walker to the Company’s board of dire...
|
|
Apr 19, 2006
|
Affymax Announces Appointment Of Arlene M. Morris To Biotechnology Industry Organization's Board Of Directors
|
9.4 KB |
|
| |
Palo Alto , CA
April 19, 2006
Affymax, Inc., a clinical-stage pharmaceutical company, today announced that Arlene M. Morris, the Company’s president and chief exe...
|
|
Apr 11, 2006
|
Affymax Begins Clinical Trial Of Hematide™ To Treat Anemia In Patients With Pure Red Cell Aplasia
|
13.1 KB |
|
| |
Palo Alto , CA
April 11, 2006
Affymax, Inc., a clinical-stage pharmaceutical company, today announced that it has initiated a clinical trial of Hematide™...
|
|
Apr 6, 2006
|
Affymax Announces Participation In Bio 2006 Annual International Convention
|
8.8 KB |
|
| |
Palo Alto , CA
April 6, 2006
Affymax, Inc., a clinical-stage pharmaceutical company, today announced that Paul B. Cleveland, chief financial officer and executive vice pr...
|
|
Apr 5, 2006
|
American Peptide Company Announces Manufacturing Clinical Supply Agreement With Affymax For Production Of Hematide™
|
10.2 KB |
|
| |
Sunnyvale, CA
April 5, 2006
American Pep...
|
|
Mar 23, 2006
|
Affymax Announces Participation in Future Leaders In The Biotech Industry Conference
|
8.9 KB |
|
| |
Palo
Alto, CA
March 23, 2006
Affymax, Inc., a clinical-stage pharmaceutical company, today announced that Arlene M. Morris, the Company’s presiden...
|
|
Feb 12, 2006
|
Affymax And Takeda Announce Agreement To Develop And Commercialize Hematide™ In Japan
|
11.6 KB |
|
| |
Palo
Alto, CA and Osaka, Japan
February 12, 2006
Affymax,
Inc. (Affymax) and Takeda Pharmaceutical Company Limited (Takeda)
...
|
|
Jan 30, 2006
|
Affymax Begins Phase 2 Clinical Trial Of Hematide™ In Patients With Anemia Associated With Cancer And Cancer Chemotherapy
|
12.4 KB |
|
| |
Palo
Alto, CA
January 30, 2006
Affymax,
Inc., a clinical-stage pharmaceutical company, today announced that
it has initiate...
|
|
Jan 5, 2006
|
Affymax Appoints Paul B. Cleveland As Chief Financial Officer And Executive Vice President Of Corporate Development
|
10.4 KB |
|
| |
Palo
Alto, CA
January 05, 2006
Affymax,
Inc., a clinical-stage pharmaceutical company, today announced the
appointment of P...
|
|
Jan 4, 2006
|
Affymax Announces Participation In 24th Annual JPMorgan Healthcare Conference
|
8.6 KB |
|
| |
Palo
Alto, CA
January 04, 2006
Affymax,
Inc., a clinical-stage pharmaceutical company, today announced that
Arlene M. Morri...
|
|
Dec 13, 2005
|
Entremed And Affymax Present Preclinical Data For Novel Angiogenesis Inhibitors
|
12.1 KB |
|
| |
Rockville,
MD and Palo Alto, CA
December 13, 2005
EntreMed,
Inc. (NASDAQ:ENMD), a clinicalstage pharmaceutical company developing
...
|
|
Dec 12, 2005
|
Hematide™ Shown In Phase 2 Trial To Stimulate Red Blood Cell Production In Patients With Anemia Due To Chronic Kidney Disease
|
11.5 KB |
|
| |
Palo
Alto, CA
December 12, 2005
Affymax, Inc., a clinical-stage pharmaceutical company, today announced
interim results from a double-blind, placebo-controlled, dose-escalation,
singl...
|
|
Dec 5, 2005
|
Affymax Announces Results Of Hematide™ Phase 2 Trial To Be Presented At 2005 American Society Of Hematology Annual Meeting
|
11.9 KB |
|
| |
Palo
Alto, CA
December 05, 2005
Affymax,
Inc., a clinical-stage pharmaceutical company, today announced that
Phase 2 clinic...
|
|
Nov 11, 2005
|
Affymax Presents Hematide™ Preclinical Data At American Society Of Nephrology Renal Week 2005
|
12.6 KB |
|
| |
Palo
Alto, CA
November 11, 2005
Affymax,
Inc., a clinical-stage pharmaceutical company, today announced the
presentation of...
|
|
Oct 13, 2005
|
Affymax Presents Hematide™ Preclinical And Clinical Data At Australian Peptide Conference
|
12.5 KB |
|
| |
Palo
Alto, CA
October 13, 2005
Affymax,
Inc., a clinical-stage pharmaceutical company, announced today the
presentation of ...
|
|
Oct 5, 2005
|
Affymax Announces Participation In Upcoming Conferences In October
|
9.0 KB |
|
| |
Palo
Alto, CA
October 05, 2005
Affymax,
Inc., a clinical-stage pharmaceutical company, today announced that
Philip Haworth,...
|
|
Sep 21, 2005
|
Affymax Begins Third Phase 2 Clinical Trial Of Hematide™
|
12.3 KB |
|
| |
Palo
Alto, CA
September 21, 2005
Affymax,
Inc. today announced that it has initiated a third Phase 2 trial
of its lead in...
|
|
|
